Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study
First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura
18-Jun-2014 -
Ablynx announced that it has achieved positive results in the Phase II TITAN study with the anti-vWF Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (TTP), a rare disorder of the blood coagulation system that causes microthrombi to form which can block small ...
Ablynx
blood coagulation
caplacizumab
+2